Screener / SEC EDGAR /CIK 0001048477 /10-K filed Feb 26, 2026, compared with Feb 24, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Biomarin Pharmaceutical Inc BMRN

Compare with peers Embed
Earnings releases

Latest results release: Nov 2, 2026

8-K item 2.02, exhibit 99

What BMRN's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Aug 4, 2025, BMRN reported $1.23 per share under GAAP and $1.44 on its own adjusted basis: the adjusted number is +17% above GAAP.

GAAP EPS $0.87, release Feb 22, 2024: Guidance for 2024 Total FY’23 Revenues of $2.42 Billion (+15% Y/Y and +20% Y/Y at Constant Currency); GAAP Diluted Earnings per Share of $0.87 (+16% Y/Y) and Non-GAAP Diluted Earning Adjusted EPS $2.08, release Feb 22, 2024: GAAP Diluted Earnings per Share of $0.87 (+16% Y/Y) and Non-GAAP Diluted Earnings per Share of $2.08 (+36% Y/Y) VOXZOGO ® Net Revenues of $1 +139% 2024-02 GAAP EPS $0.46, release Apr 24, 2024: 2024 First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and Non-GAAP Diluted Earning Adjusted EPS $0.71, release Apr 24, 2024: GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and Non-GAAP Diluted Earnings per Share of $0.71 (+18% Y/Y) VOXZOGO ® Net Product Revenues of $153 Million in Q1’24 (+74% Y/Y) +54% 2024-04 GAAP EPS $1.01, release Aug 5, 2024: First Half 2024 GAAP Diluted EPS of $1.01 (+80% Y/Y) Second Quarter 2024 Non-GAAP Diluted Earnings per Share (EPS) of $0.96 (+78% Y/Y) Adjusted EPS $0.96, release Aug 5, 2024: First Half 2024 GAAP Diluted EPS of $1.01 (+80% Y/Y) Second Quarter 2024 Non-GAAP Diluted Earnings per Share (EPS) of $0.96 (+78% Y/Y) -5% 2024-08 GAAP EPS $1.56, release Oct 29, 2024: Year-to-date 2024 GAAP Diluted EPS of $1.56 (+103% Y/Y) Third Quarter 2024 Non-GAAP Diluted EPS of $0.91 (+98% Y/Y) Adjusted EPS $0.91, release Oct 29, 2024: Year-to-date 2024 GAAP Diluted EPS of $1.56 (+103% Y/Y) Third Quarter 2024 Non-GAAP Diluted EPS of $0.91 (+98% Y/Y) -42% 2024-10 GAAP EPS $0.95, release May 1, 2025: 2025 Total Revenues of $745 million (+15% Y/Y and +17% at Constant Currency Y/Y) First Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $0.95 (+107% Y/Y) First Quarter 2025 Non-GAAP Adjusted EPS $1.13, release May 1, 2025: Currency Y/Y) First Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $0.95 (+107% Y/Y) First Quarter 2025 Non-GAAP Diluted EPS of $1.13 (+59% Y/Y) Conference Call and Webcast +19% 2025-05 GAAP EPS $1.23, release Aug 4, 2025: 2025 Total Revenues of $825 million (+16% Y/Y and +17% at Constant Currency Y/Y) Second Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $1.23 (+124% Y/Y) Second Quarter 2025 Non-GAA Adjusted EPS $1.44, release Aug 4, 2025: Currency Y/Y) Second Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $1.23 (+124% Y/Y) Second Quarter 2025 Non-GAAP Diluted EPS of $1.44 (+50% Y/Y) BioMarin Completes Acquisiti +17% 2025-08
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
ReleaseGAAP EPSAdjusted EPSGap
Aug 4, 2025 1.23 1.44 +17%
May 1, 2025 0.95 1.13 +19%
Oct 29, 2024 1.56 0.91 -42%
Aug 5, 2024 1.01 0.96 -5%
Apr 24, 2024 0.46 0.71 +54%
Feb 22, 2024 0.87 2.08 +139%
The company's words, latest release
2025 Total Revenues of $825 million (+16% Y/Y and +17% at Constant Currency Y/Y) Second Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $1.23 (+124% Y/Y) Second Quarter 2025 Non-GAA release
Currency Y/Y) Second Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $1.23 (+124% Y/Y) Second Quarter 2025 Non-GAAP Diluted EPS of $1.44 (+50% Y/Y) BioMarin Completes Acquisiti release

What the company says its adjusted numbers leave out:

Non-GAAP Income is defined by the company as GAAP Net Income (Loss) excluding amortization, stock-based compensation expense and, in certain periods, certain other specified items, as detailed below when applicable. release Nov 2, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 2, 2026 · EX-99.1

Traci McCarty Marni Kottle

Open on SEC

Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y

Updates Full-year 2026 Guidance to Reflect Order Timing Uncertainty and Impact of Two Acquired In-process Research and Development (IPR&D) Charges

Recently Announced the Addition of a New Investigational Fabry Asset to Clinical Portfolio

PDUFA Action Date of May 30, 2027 for VOXZOGO ® for the Treatment of Hypochondroplasia (HCH)

Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., November 2, 2026 – BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the third quarter ended September 30, 2026.

“BioMarin delivered a strong quarter, with revenue growth of 32%, driven by a more diversified portfolio following the acquisition of Amicus Therapeutics earlier this year and increased demand for our medicines from patients around the world. For the first time, quarterly revenue exceeded $1 billion, a milestone for BioMarin,” said Alexander Hardy, President and Chief Executive Officer of BioMarin. “We are building on this achievement by continuing to expand our pipeline through focused business development. We are excited to add our newest asset, an investigational treatment for Fabry disease, which has the potential to become the first subcutaneous enzyme therapy for this condition. With this fourth new asset added to our pipeline in 2026, we are following through on our commitment to build sustainable growth for the future.” Mr. Hardy added, “As we approach 2027, we are well positioned for our next chapter of growth, including the potential launch of VOXZOGO in hypochondroplasia and the continued execution of our financial and innovation strategy.” 1

• BioMarin is accelerating innovation by expanding its pipeline through business development. Four transactions in 2026 have added development programs from preclinical through Phase 3:

◦ BMN 450 (HM15421/GC1134A) is an investigational long-acting enzyme replacement therapy (ERT) that has the potential to be the first subcutaneous ERT for Fabry disease. Now in a global Phase 1/2 clinical study, it could extend BioMarin’s reach beyond patients with genetic variants amenable to GALAFOLD ® .

◦ BMN 440 (ALE1) for hypophosphatasia (HPP) is a potential first-in-class oral therapy for HPP. The Phase 1/2a study in healthy volunteers and adults with HPP is ongoing, with data expected in 2027.

◦ BMN 430 for ReNU syndrome has the potential to be a first-in-disease antisense oligonucleotide (ASO) medicine for ReNU syndrome, a serious, rare neurodevelopmental condition with no approved targeted therapies. Preclinical studies are underway to identify a lead ASO candidate.

◦ BMN 820 (DMX-200) for focal segmental glomerulosclerosis (FSGS) is a first-in- class oral CCR2 inhibitor for which BioMarin holds exclusive U.S. commercialization rights. The Phase 3 ACTION 3 trial is fully enrolled, with pivotal data expected in 2028.

• Today, BioMarin announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA target action date of May 30, 2027 for its supplemental NDA to expand the use of VOXZOGO for the treatment of HCH, the first potential targeted therapy for the condition. BioMarin also announced today that the European Medicines Agency (EMA) validated its submission for the approval of VOXZOGO to treat HCH.

• BioMarin’s application for full approval of VOXZOGO in children with achondroplasia is under review by the FDA, with a PDUFA target action date of February 28, 2027. The application includes long-term safety and efficacy data, such as final adult height and clinical outcomes beyond linear growth.

• The Phase 2/3 study for BMN 333, BioMarin's long-acting C-type natriuretic peptide (CNP) for achondroplasia, continues to enroll on track. Dose-response data from this study is expected in 2027.

• In October, five-year results from the PROPEL open-label extension study with POMBILITI ® + OPFOLDA ® were presented in a late-breaking presentation at the World Muscle Society Annual Congress. In adults with late-onset Pompe disease, POMBILITI + OPFOLDA demonstrated durable motor function outcomes and relative stabilization of pulmonary function. This included people who had received enzyme replacement therapy for a mean of 7.6 years before enrolling. No new safety signals were identified.

• For BMN 351, BioMarin’s Phase 1/2 candidate for Duchenne muscular dystrophy, the company expects to provide a program update by year-end.

• In the first full quarter as part of BioMarin, GALAFOLD and POMBILITI + OPFOLDA delivered strong quarterly revenue, contributing $152 million and $49 million, respectively. The number of patients treated with GALAFOLD and POMBILITI + OPFOLDA increased by approximately 13% and 69% Y/Y, respectively. POMBILITI + OPFOLDA uptake benefited from supply constraints for other Pompe therapies.

• Metabolic Conditions revenue grew 44% Y/Y in the third quarter of 2026 and 26% Y/Y year-to-date. Growth was driven by the additions of GALAFOLD and POMBILITI + OPFOLDA and by higher VIMIZIM ® revenue. The number of patients on therapy increased across all BioMarin-marketed Metabolic Conditions therapies, Y/Y.

• VOXZOGO revenue grew 12% Y/Y in the third quarter of 2026, and the number of children treated with VOXZOGO globally increased 17% Y/Y. As of the end of the quarter, children with achondroplasia in 58 countries around the world were being treated with VOXZOGO. More than 75% of VOXZOGO revenue was generated outside of the U.S., and a large international order previously expected in the third quarter is now anticipated in the fourth quarter. In the U.S., the majority of new patient starts were in children under the age of two. 2

• BioMarin continued to integrate Amicus in the third quarter, realizing accelerated cost synergies to enable investments in initiatives to drive future growth of GALAFOLD and POMBILITI + OPFOLDA. BioMarin continues to expect approximately $280 million of GAAP cost synergies (approximately $220 million on a Non-GAAP basis) to be fully realized in 2028.

• On August 30, 2026, the company announced the global settlement of all outstanding claims with Ascendis Pharma A/S related to its product Yuviwel. As part of the agreement, Ascendis will pay BioMarin a royalty equal to 20% of net sales of Yuviwel in the U.S., retroactive to the first commercial sale, and 18% of net sales in the European Union, Brazil and South Korea until May 2030.

for the third quarter of 2026 were $1,025 million, an increase of 32% compared to the same period in 2025, primarily driven by revenues from GALAFOLD and POMBILITI + OPFOLDA, which were acquired on April 27, 2026, as well as 18% revenue growth in VIMIZIM due to timing of large international orders. In the quarter, VOXZOGO revenue also increased by 12% due to new patients initiating therapy. These increases were partially offset by a decrease in NAGLAZYME ® revenue due to timing of large international orders.

increased to $123 million compared to $31 million for the same period in 2025. The increase was primarily driven by the acquisition of Amicus Therapeutics (Amicus), including intangible asset amortization, interest expense from debt issued to finance a portion of the transaction, amortization of inventory fair value step-up, and integration and restructuring costs. The increase was also attributed to acquired in-process research and development (IPR&D) charges recorded in the quarter in connection with the acquisition of Alesta Therapeutics (Alesta). These increases were partially offset by revenue growth as described above.

for the third quarter of 2026 increased to $45 million compared to $22 million for the same period in 2025. The increase was primarily driven by revenue growth, partially offset by higher acquired IPR&D charges and higher interest expense, as described above. The increases were also partially offset by higher sales and marketing spend related to GALAFOLD and POMBILITI + OPFOLDA. 3

Financial Highlights (in millions of U.S. dollars, except percentages and per share data, unaudited)

NM Percentage change is not meaningful for products acquired from Amicus on April 27, 2026.

(2) Refer to Non-GAAP Information beginning on page 10 of this press release for definitions of Non-GAAP Income, Non-GAAP Operating Margin percentage and Non- GAAP Diluted EPS along with the related reconciliations to the comparable information reported under U.S. GAAP.

(3) GAAP Operating Margin percentage is defined by the company as GAAP Income (Loss) from Operations divided by Total Revenues. 4

BioMarin does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking Non-GAAP financial measures to the most directly comparable GAAP reported financial measures because the company is unable to predict with reasonable certainty the financial impact of changes resulting from its strategic portfolio and business operating model reviews; potential future asset impairments; gains and losses on investments; and other unusual gains and losses without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. As such, any reconciliations provided would imply a degree of precision that could be confusing or misleading to investors.

• Revenue: Total Revenues, Metabolic Conditions, and VOXZOGO guidance updated to reflect uncertainty in the timing of multiple orders from a single international customer.

• Non-GAAP Diluted EPS: BioMarin expects the Alesta acquisition and BMN 450 license agreement to result in total pre-tax charges of approximately $320 million and $83 million, respectively, for the full year 2026, consisting of the acquired IPR&D charges and ongoing operating expenses, representing an unfavorable impact of approximately $1.55 and $0.32, respectively, to both GAAP Diluted EPS and Non-GAAP Diluted EPS for the full year 2026.

(2) Refer to Non-GAAP Information beginning on page 10 of this press release for definition of Non-GAAP Diluted EPS.

(3) Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted- Average Diluted Shares Outstanding. BioMarin will host a conference call and webcast to discuss third quarter 2026 financial results today, Monday, November 2, 2026, at 4:30 p.m. ET. This event can be accessed through this link or on the investor section of the BioMarin website at www.biomarin.com.

U.S./Canada Dial-in Number:+1 Replay Dial-in Number: +1 833-309-1852 833-461-5787 International Dial-in Number: +1 Replay International Dial-in Number: +44 626-884-3620 800 007 4044 Conference ID: 324 588 583 Conference ID: 324 588 583

BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com. 5

This press release and the associated conference call and webcast contain forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: future financial performance, including the expectations of Revenues and Non- GAAP Diluted EPS for, in certain instances, the full-year 2026 and fourth quarter of 2026, and future periods, and the underlying drivers of those results, such as the expected demand and continued growth of BioMarin’s Metabolic Conditions portfolio, including PALYNZIQ, GALAFOLD and POMBILITI + OPFOLDA, and VOXZOGO, and the expected impact of the acquisition of Alesta Therapeutics B.V. (Alesta) and the BMN 450 license agreement; the anticipated benefits of the acquisition of Amicus Therapeutics, Inc., including the expected amount and timing of cost synergies as well as expected revenue from the addition of GALAFOLD and POMBILITI + OPFOLDA; the anticipated benefits of the acquisition of Alesta; the anticipated benefits of the BMN 450 license agreement; the anticipated benefits of the global settlement with Ascendis Pharma A/S, including BioMarin’s expected receipt of royalty payments on net sales of Yuviwel in the United States, the European Union, Brazil and South Korea; BioMarin’s plans for investment in innovation and future growth; the timing of orders for commercial products; plans and expectations regarding the development, commercialization and commercial prospects of BioMarin’s product candidates and commercial products, including the prospects and timing of actions relating to clinical studies and trials and product approvals, such as study initiations, study advancements, data readouts, submissions, filings, approvals, and label expansions; the expected benefits and availability of BioMarin’s commercial products and product candidates, including with respect to the potential new indication for VOXZOGO in hypochondroplasia; and potential growth opportunities and trends, including the assumptions and expectations regarding total addressable patient population (TAPP) with respect to the conditions targeted by BioMarin’s product candidates and commercial products.

These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: BioMarin’s success in the commercialization of its commercial products; BioMarin’s ability to successfully integrate and realize the anticipated benefits of any acquisitions and license agreements; BioMarin’s ability to accurately estimate future financial performance; impacts of macroeconomic and other external factors on BioMarin’s operations, regulatory uncertainty, the impact of new or increased tariffs, other trade protection measures, and escalating trade tensions; geopolitical instability, wars and military conflicts; results and timing of current and planned preclinical studies and clinical trials and the release of data from those trials; BioMarin’s ability to successfully manufacture its commercial products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Medicines Agency, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products; BioMarin’s ability to meet product demand; actual sales of BioMarin’s commercial products; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption “Risk Factors” in BioMarin's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin ® , VOXZOGO ® , VIMIZIM ® , NAGLAZYME ® , PALYNZIQ ® , BRINEURA ® , KUVAN ® , ROCTAVIAN ® , GALAFOLD ® , and POMBILITI ® + OPFOLDA ® are registered trademarks of BioMarin Pharmaceutical Inc., or its affiliates. ALDURAZYME ® is a registered trademark of BioMarin/Genzyme LLC. All other brand names and service marks, trademarks and other trade names appearing in this release are the property of their respective owners. 6

September 30, December 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── -Unaudited ASSETS Current assets: Cash and cash $ 736,007 $ 1,311,679 equivalents Short-term — 248,930 investments Accounts receivable, 1,076,355 908,214 net Inventory 1,796,069 1,298,883 Other current 312,205 185,784 assets Total current 3,920,636 3,953,490 assets Noncurrent assets: Long-term — 492,242 investments Property, plant and 980,081 952,508 equipment, net Intangible 4,777,247 213,837 assets, net Goodwill 666,367 196,199 Deferred tax 897,787 1,508,697 assets Other assets 327,113 277,049 Total assets $ 11,569,231 $ 7,594,022 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable and $ 946,107 $ 759,031 accrued liabilities Current portion of 658,717 — long-term debt, net Total current 1,604,824 759,031 liabilities Noncurrent liabilities: Long-term 3,514,974 597,176 debt, net Other long-term 193,401 150,816 liabilities Total 5,313,199 1,507,023 liabilities Stockholders’ equity: Common stock, $0.001 par value: 500,000,000 shares authorized; 193,676,831 194 192 and 192,300,101 shares issued and outstanding, respectively Additional paid-in 6,089,036 5,956,582 capital Company common stock held by the Nonqualified -10,851 -10,508 Deferred Compensation Plan Accumulated other -4,011 -13,473 comprehensive loss Retained 181,664 154,206 earnings Total stockholders’ 6,256,032 6,086,999 equity Total liabilities and $ 11,569,231 $ 7,594,022 stockholders’ equity

CASH FLOWS FROM Nine Months Ended OPERATING September 30, ACTIVITIES: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 27,458 $ 395,474 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 244,514 59,119 amortization Non-cash interest 30,548 1,969 expense Stock-based 172,684 134,496 compensation Impairment of assets 15,203 2,967 Acquired IPR&D 282,258 220,963 expense Deferred income -27,490 48,125 taxes Unrealized foreign exchange losses -8,380 244 (gains) Other -7,091 -5,399 Changes in operating assets and liabilities, net of effects of business acquired:

Accounts receivable, -60,435 -107,378 net Inventory -1,621 -98,796 Other current assets -54,369 -32,125 Other assets 12,859 -32,679 Accounts payable and -52,675 119,478 accrued liabilities Other long-term 3,511 21,892 liabilities Net cash provided by operating 576,974 728,350 activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property, plant and -78,032 -62,316 equipment Maturities and sales 767,277 294,547 of investments Purchases of -25,792 -313,262 investments Business combination, net of -5,067,630 — cash acquired Purchases of IPR&D, -277,881 -285,193 net of cash acquired Other investing -1,191 -5,569 activities, net Net cash used in -4,683,249 -371,793 investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from exercises of awards under 6,655 7,714 equity incentive plans Taxes paid related to net share -43,330 -53,265 settlement of equity awards Proceeds from 3,650,000 — borrowings Payments of debt -65,605 — issuance costs Repayments of -15,000 — borrowings Net cash provided by (used in) financing 3,532,720 -45,551 activities Effect of exchange -2,117 -3,740 rate changes on cash NET INCREASE (DECREASE) IN CASH -575,672 307,266 AND CASH EQUIVALENTS Cash and cash equivalents: Beginning of period $ 1,311,679 $ 942,842 End of period $ 736,007 $ 1,250,108

The results presented in this press release include both GAAP information and Non-GAAP information. Non-GAAP Income is defined by the company as GAAP Net Income (Loss) excluding amortization, stock-based compensation expense and, in certain periods, certain other specified items, as detailed below when applicable. The company also includes a Non-GAAP adjustment for the estimated tax impact of the reconciling items. Non-GAAP Cost of Sales (COS), Non-GAAP R&D expenses and Non-GAAP Selling, General and Administrative (SG&A) expenses are defined by the company as GAAP COS, GAAP R&D expenses and GAAP SG&A expenses, respectively, excluding stock-based compensation expense and, in certain periods, certain other specified items, as detailed below when applicable. Non- GAAP Operating Margin percentage is defined by the company as GAAP Income (Loss) from Operations, excluding amortization of intangible assets, stock-based compensation expense and, in certain periods, certain other specified items, divided by GAAP Total Revenues. Non-GAAP Diluted EPS is defined by the company as Non-GAAP Income divided by Non-GAAP Weighted-Average Diluted Shares Outstanding. Non-GAAP Weighted-Average Diluted Shares Outstanding is defined by the company as GAAP Weighted-Average Diluted Shares Outstanding, adjusted to include any common shares issuable under the company’s equity plans or convertible debt in periods when they are dilutive under Non-GAAP. Non-GAAP synergies is defined by the company as Amicus’ legacy labor and external spend cost reductions, excluding the impact of stock-based compensation.

BioMarin regularly uses both GAAP and Non-GAAP results and expectations internally to assess its financial operating performance and evaluate key business decisions related to its principal business activities: the discovery, development, manufacture, marketing and sale of innovative biologic therapies. BioMarin also uses Non-GAAP Income internally to understand, manage and evaluate its business and to make operating decisions, and compensation of executives is based in part on this measure. Because these Non-GAAP metrics are important internal measurements for BioMarin, the company believes that providing this information in conjunction with BioMarin’s GAAP information enhances investors’ and analysts’ ability to meaningfully compare the company’s results from period to period and to its forward-looking guidance, and to identify operating trends in the company’s principal business.

Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for, or superior to comparable GAAP measures and should be read in conjunction with the consolidated financial information prepared in accordance with GAAP. Investors should note that the Non-GAAP information is not prepared under any comprehensive set of accounting rules or principles and does not reflect all of the amounts associated with the company’s results of operations as determined in accordance with GAAP. Investors should also note that these Non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its Non-GAAP financial measures; likewise, the company may in the future cease to exclude items that it has historically excluded for purposes of its Non-GAAP financial measures. Because of the non-standardized definitions, the Non-GAAP financial measure as used by BioMarin in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

The following tables present the reconciliation of GAAP reported to Non-GAAP adjusted financial information: 10

(2) Stock-based compensation expense recorded in SG&A for the nine months ended September 30, 2026, includes approximately $13 million related to the post- combination service period for unvested Amicus stock options.

(3) Represents amortization of the inventory step-up for the inventory acquired in the Amicus transaction.

(4) The 2026 amounts represent severance, transaction and integration costs resulting from the Amicus acquisition, as well as restructuring costs incurred in connection with corporate initiatives. The 2025 amounts represent severance costs incurred in connection with the acquisition of Inozyme Pharma, Inc.

(5) Represents impairment loss on non-marketable equity securities recorded in Other income, net, in the first quarter of 2025.

(6) Common stock issuable under the company’s equity plans and convertible debt were excluded from the computation of GAAP and Non-GAAP Weighted-Average Diluted Shares Outstanding in the periods they were anti-dilutive. 12

Full text with the tables
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                
  Contact:                                                      
  Investors:                      Media:                        
  Traci McCarty                   Marni Kottle                  
  BioMarin Pharmaceutical Inc.    BioMarin Pharmaceutical Inc.  
  (415) 455-7558                  (650) 374-2803                
                                                                
      BioMarin Reports Third Quarter 2026 Financial and Operating Results       
                                                                                
 Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth  
Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal
                                 Conditions Y/Y                                 
                                                                                
 Updates Full-year 2026 Guidance to Reflect Order Timing Uncertainty and Impact 
      of Two Acquired In-process Research and Development (IPR&D) Charges       
                                                                                
Recently Announced the Addition of a New Investigational Fabry Asset to Clinical
                                   Portfolio                                    
                                                                                
      PDUFA Action Date of May 30, 2027 for VOXZOGO ® for the Treatment of      
                            Hypochondroplasia (HCH)                             
                                                                                
          Conference Call and Webcast Scheduled Today at 4:30 p.m. ET           
SAN RAFAEL, Calif., November 2, 2026 – BioMarin Pharmaceutical Inc. (NASDAQ:
BMRN) today announced financial results for the third quarter ended September
30, 2026.

“BioMarin delivered a strong quarter, with revenue growth of 32%, driven by a
more diversified portfolio following the acquisition of Amicus Therapeutics
earlier this year and increased demand for our medicines from patients around
the world. For the first time, quarterly revenue exceeded $1 billion, a
milestone for BioMarin,” said Alexander Hardy, President and Chief Executive
Officer of BioMarin. “We are building on this achievement by continuing to
expand our pipeline through focused business development. We are excited to add
our newest asset, an investigational treatment for Fabry disease, which has the
potential to become the first subcutaneous enzyme therapy for this condition.
With this fourth new asset added to our pipeline in 2026, we are following
through on our commitment to build sustainable growth for the future.” Mr. Hardy
added, “As we approach 2027, we are well positioned for our next chapter of
growth, including the potential launch of VOXZOGO in hypochondroplasia and the
continued execution of our financial and innovation strategy.”
                                       1                                        
                                                                                
   2026 Business and Pipeline Highlights                                        
                                                                                
                                                                                
  Innovation                                                                    
                                                                                
• BioMarin is accelerating innovation by expanding its pipeline through business
development. Four transactions in 2026 have added development programs from
preclinical through Phase 3:

◦ BMN 450 (HM15421/GC1134A) is an investigational long-acting enzyme replacement
therapy (ERT) that has the potential to be the first subcutaneous ERT for Fabry
disease. Now in a global Phase 1/2 clinical study, it could extend BioMarin’s
reach beyond patients with genetic variants amenable to GALAFOLD ® .

◦ BMN 440 (ALE1) for hypophosphatasia (HPP) is a potential first-in-class oral
therapy for HPP. The Phase 1/2a study in healthy volunteers and adults with HPP
is ongoing, with data expected in 2027.

◦ BMN 430 for ReNU syndrome has the potential to be a first-in-disease antisense
oligonucleotide (ASO) medicine for ReNU syndrome, a serious, rare
neurodevelopmental condition with no approved targeted therapies. Preclinical
studies are underway to identify a lead ASO candidate.

◦ BMN 820 (DMX-200) for focal segmental glomerulosclerosis (FSGS) is a first-in-
class oral CCR2 inhibitor for which BioMarin holds exclusive U.S.
commercialization rights. The Phase 3 ACTION 3 trial is fully enrolled, with
pivotal data expected in 2028.

• Today, BioMarin announced that the U.S. Food and Drug Administration (FDA) has
set a PDUFA target action date of May 30, 2027 for its supplemental NDA to
expand the use of VOXZOGO for the treatment of HCH, the first potential targeted
therapy for the condition. BioMarin also announced today that the European
Medicines Agency (EMA) validated its submission for the approval of VOXZOGO to
treat HCH.

• BioMarin’s application for full approval of VOXZOGO in children with
achondroplasia is under review by the FDA, with a PDUFA target action date of
February 28, 2027. The application includes long-term safety and efficacy data,
such as final adult height and clinical outcomes beyond linear growth.

• The Phase 2/3 study for BMN 333, BioMarin's long-acting C-type natriuretic
peptide (CNP) for achondroplasia, continues to enroll on track. Dose-response
data from this study is expected in 2027.

• In October, five-year results from the PROPEL open-label extension study with
POMBILITI ® + OPFOLDA ® were presented in a late-breaking presentation at the
World Muscle Society Annual Congress. In adults with late-onset Pompe disease,
POMBILITI + OPFOLDA demonstrated durable motor function outcomes and relative
stabilization of pulmonary function. This included people who had received
enzyme replacement therapy for a mean of 7.6 years before enrolling. No new
safety signals were identified.

• For BMN 351, BioMarin’s Phase 1/2 candidate for Duchenne muscular dystrophy,
the company expects to provide a program update by year-end.
                                                                                
  Growth                                                                        
                                                                                
• In the first full quarter as part of BioMarin, GALAFOLD and POMBILITI +
OPFOLDA delivered strong quarterly revenue, contributing $152 million and $49
million, respectively. The number of patients treated with GALAFOLD and
POMBILITI + OPFOLDA increased by approximately 13% and 69% Y/Y, respectively.
POMBILITI + OPFOLDA uptake benefited from supply constraints for other Pompe
therapies.

• Metabolic Conditions revenue grew 44% Y/Y in the third quarter of 2026 and 26%
Y/Y year-to-date. Growth was driven by the additions of GALAFOLD and POMBILITI +
OPFOLDA and by higher VIMIZIM ® revenue. The number of patients on therapy
increased across all BioMarin-marketed Metabolic Conditions therapies, Y/Y.

• VOXZOGO revenue grew 12% Y/Y in the third quarter of 2026, and the number of
children treated with VOXZOGO globally increased 17% Y/Y. As of the end of the
quarter, children with achondroplasia in 58 countries around the world were
being treated with VOXZOGO. More than 75% of VOXZOGO revenue was generated
outside of the U.S., and a large international order previously expected in the
third quarter is now anticipated in the fourth quarter. In the U.S., the
majority of new patient starts were in children under the age of two.
                                       2                                        
                                                                                
  Value Commitment                                                              
                                                                                
• BioMarin continued to integrate Amicus in the third quarter, realizing
accelerated cost synergies to enable investments in initiatives to drive future
growth of GALAFOLD and POMBILITI + OPFOLDA. BioMarin continues to expect
approximately $280 million of GAAP cost synergies (approximately $220 million on
a Non-GAAP basis) to be fully realized in 2028.

• On August 30, 2026, the company announced the global settlement of all
outstanding claims with Ascendis Pharma A/S related to its product Yuviwel. As
part of the agreement, Ascendis will pay BioMarin a royalty equal to 20% of net
sales of Yuviwel in the U.S., retroactive to the first commercial sale, and 18%
of net sales in the European Union, Brazil and South Korea until May 2030.
                                                                                
  Third Quarter 2026 Financial Highlights                                       
                                                                                
•
                                                                                
  Total Revenues                                                                
                                                                                
for the third quarter of 2026 were $1,025 million, an increase of 32% compared
to the same period in 2025, primarily driven by revenues from GALAFOLD and
POMBILITI + OPFOLDA, which were acquired on April 27, 2026, as well as 18%
revenue growth in VIMIZIM due to timing of large international orders. In the
quarter, VOXZOGO revenue also increased by 12% due to new patients initiating
therapy. These increases were partially offset by a decrease in NAGLAZYME ®
revenue due to timing of large international orders.

•
                                                                                
  GAAP Net Loss                                                                 
                                                                                
increased to $123 million compared to $31 million for the same period in 2025.
The increase was primarily driven by the acquisition of Amicus Therapeutics
(Amicus), including intangible asset amortization, interest expense from debt
issued to finance a portion of the transaction, amortization of inventory fair
value step-up, and integration and restructuring costs. The increase was also
attributed to acquired in-process research and development (IPR&D) charges
recorded in the quarter in connection with the acquisition of Alesta
Therapeutics (Alesta). These increases were partially offset by revenue growth
as described above.
                                                                                
  •                                                                             
                                                                                
                                                                                
  Non-GAAP Income                                                               
                                                                                
for the third quarter of 2026 increased to $45 million compared to $22 million
for the same period in 2025. The increase was primarily driven by revenue
growth, partially offset by higher acquired IPR&D charges and higher interest
expense, as described above. The increases were also partially offset by higher
sales and marketing spend related to GALAFOLD and POMBILITI + OPFOLDA.
                                       3                                        
                                                                                
 Financial Highlights (in millions of U.S. dollars, except percentages and per  
                             share data, unaudited)                             
                                                                                
                Three                               Nine                        
               Months                             Months                        
                Ended                              Ended                        
             Septemb…                           Septemb…                        
                  30,                                30,                        
                 2026       2025    % Change        2026      2025    % Change  
  Total        $1,025       $776    32%           $2,781    $2,347    18%       
  Revenu…                                                                       
  Net                                                                           
  Product                                                                       
  Revenu…                                                                       
  by                                                                            
  Produc…                                                                       
  VOXZOGO        $245       $218    12%             $717      $654    10%       
  Metabo…                                                                       
  Condit…                                                                       
  VIMIZIM        $216       $183    18%             $620      $587    6%        
  NAGLAZ…         108        122    (11)%            373       365    2%        
  PALYNZ…         111        109    2%               336       308    9%        
  GALAFO…         152          —    NM               258         —    NM        
  BRINEU…          53         48    10%              151       137    10%       
  ALDURA…          57         54    6%               137       159    (14)%     
  POMBIL…                                                                       
  +                49          —    NM                79         —    NM        
  OPFOLDA                                                                       
  Total                                                                         
  Metabo…        $744       $516    44%           $1,954    $1,556    26%       
  Condit…                                                                       
  Revenue                                                                       
  KUVAN®          $23        $24    (4)%             $71       $76    (7)%      
  ROCTAV…          $1         $3    (67)%            $15       $23    (35)%     
  GAAP                                                                          
  Net          $(123)      $(31)    297%             $27      $395    (93)%     
  Income                                                                        
  (Loss)                                                                        
  Non-GA…         $45        $22    105%            $430      $525    (18)%     
  Income…                                                                       
  GAAP                                                                          
  Operat…      (8.0)%     (6.0)%                    5.7%     19.4%              
  Margin                                                                        
  %(3)                                                                          
  Non-GA…                                                                       
  Operat…       13.4%       2.8%                   24.6%     26.3%              
  Margin                                                                        
  %(2)                                                                          
  GAAP                                                                          
  Diluted     $(0.63)    $(0.16)    294%           $0.14     $2.04    (93)%     
  EPS                                                                           
  Non-GA…                                                                       
  Diluted       $0.23      $0.12    92%            $2.18     $2.69    (19)%     
  EPS(2)                                                                        
                                                                                
NM Percentage change is not meaningful for products acquired from Amicus on
April 27, 2026.

(1) In 2026, the company announced that it will no longer market ROCTAVIAN.

(2) Refer to Non-GAAP Information beginning on page 10 of this press release for
definitions of Non-GAAP Income, Non-GAAP Operating Margin percentage and Non-
GAAP Diluted EPS along with the related reconciliations to the comparable
information reported under U.S. GAAP.

(3) GAAP Operating Margin percentage is defined by the company as GAAP Income
(Loss) from Operations divided by Total Revenues.
                                       4                                        
                                                                                
   Forward-Looking Non-GAAP Financial Information                               
                                                                                
BioMarin does not provide guidance for GAAP reported financial measures (other
than revenue) or a reconciliation of forward-looking Non-GAAP financial measures
to the most directly comparable GAAP reported financial measures because the
company is unable to predict with reasonable certainty the financial impact of
changes resulting from its strategic portfolio and business operating model
reviews; potential future asset impairments; gains and losses on investments;
and other unusual gains and losses without unreasonable effort. These items are
uncertain, depend on various factors, and could have a material impact on GAAP
reported results for the guidance period. As such, any reconciliations provided
would imply a degree of precision that could be confusing or misleading to
investors.

Updated 2026 Full-Year Financial Guidance (in millions, except EPS amounts)

• Revenue: Total Revenues, Metabolic Conditions, and VOXZOGO guidance updated to
reflect uncertainty in the timing of multiple orders from a single international
customer.

• Non-GAAP Diluted EPS: BioMarin expects the Alesta acquisition and BMN 450
license agreement to result in total pre-tax charges of approximately $320
million and $83 million, respectively, for the full year 2026, consisting of the
acquired IPR&D charges and ongoing operating expenses, representing an
unfavorable impact of approximately $1.55 and $0.32, respectively, to both GAAP
Diluted EPS and Non-GAAP Diluted EPS for the full year 2026.
                                                                                
             Provided                                                           
                   on                     Updated                    Midpoint   
               August                    November                    Growth     
  Item        6, 2026                     2, 2026                    (Y/Y)      
 ────────────────────────────────────────────────────────────────────────────── 
  Total        $3,875    to    $3,925      $3,800    to    $3,900    20%        
  Revenu…                                                                       
  Metabo…      $2,725    to    $2,775      $2,675    to    $2,750    29%        
  Condit…                                                                       
  VOXZOGO      $1,000    to    $1,050        $975    to    $1,025    8%         
  Other          $100    to      $125        $125    to      $150               
  Revenu…                                                                       
  Non-GA…                                                                       
  Diluted       $4.90    to     $5.10       $2.80    to     $3.10    (6)%       
  EPS(2)…                                                                       
                                                                                
(1) Other Revenues includes KUVAN, ROCTAVIAN, and royalties.

(2) Refer to Non-GAAP Information beginning on page 10 of this press release for
definition of Non-GAAP Diluted EPS.

(3) Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-
Average Diluted Shares Outstanding.
BioMarin will host a conference call and webcast to discuss third quarter 2026
financial results today, Monday, November 2, 2026, at 4:30 p.m. ET. This event
can be accessed through this link or on the investor section of the BioMarin
website at www.biomarin.com.
                                                                                
  U.S./Canada Dial-in Number:+1       Replay Dial-in Number: +1 833-309-1852    
  833-461-5787                                                                  
  International Dial-in Number: +1    Replay International Dial-in Number: +44  
  626-884-3620                        800 007 4044                              
  Conference ID:  324 588 583         Conference ID: 324 588 583                
                                                                                
                                                                                
  About BioMarin                                                                
                                                                                
BioMarin is a leading, global rare disease biotechnology company focused on
delivering medicines for people living with genetically defined conditions.
Founded in 1997, the San Rafael, California-based company has a proven track
record of innovation, with nine commercial therapies and a strong clinical and
preclinical pipeline. Using a distinctive approach to drug discovery and
development, BioMarin seeks to unleash the full potential of genetic science by
pursuing category-defining medicines that have a profound impact on patients. To
learn more, please visit www.biomarin.com.
                                       5                                        
                                                                                
  Forward-Looking Statements                                                    
                                                                                
This press release and the associated conference call and webcast contain
forward-looking statements about the business prospects of BioMarin
Pharmaceutical Inc. (BioMarin), including, without limitation, statements about:
future financial performance, including the expectations of Revenues and Non-
GAAP Diluted EPS for, in certain instances, the full-year 2026 and fourth
quarter of 2026, and future periods, and the underlying drivers of those
results, such as the expected demand and continued growth of BioMarin’s
Metabolic Conditions portfolio, including PALYNZIQ, GALAFOLD and POMBILITI +
OPFOLDA, and VOXZOGO, and the expected impact of the acquisition of Alesta
Therapeutics B.V. (Alesta) and the BMN 450 license agreement; the anticipated
benefits of the acquisition of Amicus Therapeutics, Inc., including the expected
amount and timing of cost synergies as well as expected revenue from the
addition of GALAFOLD and POMBILITI + OPFOLDA; the anticipated benefits of the
acquisition of Alesta; the anticipated benefits of the BMN 450 license
agreement; the anticipated benefits of the global settlement with Ascendis
Pharma A/S, including BioMarin’s expected receipt of royalty payments on net
sales of Yuviwel in the United States, the European Union, Brazil and South
Korea; BioMarin’s plans for investment in innovation and future growth; the
timing of orders for commercial products; plans and expectations regarding the
development, commercialization and commercial prospects of BioMarin’s product
candidates and commercial products, including the prospects and timing of
actions relating to clinical studies and trials and product approvals, such as
study initiations, study advancements, data readouts, submissions, filings,
approvals, and label expansions; the expected benefits and availability of
BioMarin’s commercial products and product candidates, including with respect to
the potential new indication for VOXZOGO in hypochondroplasia; and potential
growth opportunities and trends, including the assumptions and expectations
regarding total addressable patient population (TAPP) with respect to the
conditions targeted by BioMarin’s product candidates and commercial products.

These forward-looking statements are predictions and involve risks and
uncertainties such that actual results may differ materially from these
statements. These risks and uncertainties include, among others: BioMarin’s
success in the commercialization of its commercial products; BioMarin’s ability
to successfully integrate and realize the anticipated benefits of any
acquisitions and license agreements; BioMarin’s ability to accurately estimate
future financial performance; impacts of macroeconomic and other external
factors on BioMarin’s operations, regulatory uncertainty, the impact of new or
increased tariffs, other trade protection measures, and escalating trade
tensions; geopolitical instability, wars and military conflicts; results and
timing of current and planned preclinical studies and clinical trials and the
release of data from those trials; BioMarin’s ability to successfully
manufacture its commercial products and product candidates; the content and
timing of decisions by the U.S. Food and Drug Administration, the European
Medicines Agency, the European Commission and other regulatory authorities
concerning each of the described products and product candidates; the market for
each of these products; BioMarin’s ability to meet product demand; actual sales
of BioMarin’s commercial products; and those factors detailed in BioMarin's
filings with the Securities and Exchange Commission, including, without
limitation, the factors contained under the caption “Risk Factors” in BioMarin's
Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as such
factors may be updated by any subsequent reports. Investors are urged not to
place undue reliance on forward-looking statements, which speak only as of the
date hereof. BioMarin is under no obligation, and expressly disclaims any
obligation to update or alter any forward-looking statement, whether as a result
of new information, future events or otherwise.

BioMarin ® , VOXZOGO ® , VIMIZIM ® , NAGLAZYME ® , PALYNZIQ ® , BRINEURA ® ,
KUVAN ® , ROCTAVIAN ® , GALAFOLD ® , and POMBILITI ® + OPFOLDA ® are registered
trademarks of BioMarin Pharmaceutical Inc., or its affiliates. ALDURAZYME ® is a
registered trademark of BioMarin/Genzyme LLC. All other brand names and service
marks, trademarks and other trade names appearing in this release are the
property of their respective owners.
                                       6                                        
                                                                                
                          BIOMARIN PHARMACEUTICAL INC.                          
                                                                                
                                                                                
                  CONDENSED CONSOLIDATED STATEMENTS OF INCOME                   
                                                                                
            Three and Nine Months Ended September 30, 2026 and 2025             
                                                                                
            (In thousands of U.S. dollars, except per share amounts)            
                                                                                
                                  (Unaudited)                                   
                                                                                
           Three                               Nine                             
           Months                              Months                           
           Ended                               Ended                            
           Septem…                             Septe…                           
           30,                                 30,                              
  REVE…    2026               2025             2026               2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  prod…    $        1,013…    $     760,812    $       2,757,…    $     2,308…  
  reve…                                                                         
  Roya…                                                                         
  and               11,566           15,321             23,011          38,250  
  other                                                                         
  reve…                                                                         
  Total             1,024…          776,133            2,780,…          2,346…  
  reve…                                                                         
  OPER…                                                                         
  EXPE…                                                                         
  Cost                                                                          
  of                205,4…          140,085            603,210          441,7…  
  sales                                                                         
  Rese…                                                                         
  and               180,5…          188,515            566,273          508,5…  
  deve…                                                                         
  Acqu…                                                                         
  in-p…                                                                         
  rese…             287,6…          220,963            287,685          220,9…  
  and                                                                           
  deve…                                                                         
  (IPR…                                                                         
  Sell…                                                                         
  gene…             333,6…          268,415            987,482          706,8…  
  and                                                                           
  admi…                                                                         
  Inta…                                                                         
  asset             99,458            4,847            177,433          14,540  
  amor…                                                                         
  Total                                                                         
  oper…             1,106…          822,825            2,622,…          1,892…  
  expe…                                                                         
  INCO…                                                                         
  (LOS…             -82,0…          -46,692            158,479          454,0…  
  FROM                                                                          
  OPER…                                                                         
  Inte…              4,630           17,854             37,670          55,694  
  inco…                                                                         
  Inte…             -55,6…           -2,579            -133,8…          -8,121  
  expe…                                                                         
  Other                                                                         
  inco…              1,310            5,093              8,550           7,972  
  net                                                                           
  INCO…                                                                         
  (LOS…                                                                         
  BEFO…             -131,…          -26,324             70,818          509,6…  
  INCO…                                                                         
  TAXES                                                                         
  Prov…                                                                         
  for                                                                           
  (ben…             -8,938            4,420             43,360          114,1…  
  from)                                                                         
  inco…                                                                         
  taxes                                                                         
  NET                                                                           
  INCO…    $        -122,…    $     -30,744    $        27,458    $     395,4…  
  (LOS…                                                                         
  EARN…                                                                         
  (LOS…                                                                         
  PER      $         -0.63    $       -0.16    $          0.14    $       2.06  
  SHAR…                                                                         
  BASIC                                                                         
  EARN…                                                                         
  (LOS…                                                                         
  PER      $         -0.63    $       -0.16    $          0.14    $       2.04  
  SHAR…                                                                         
  DILU…                                                                         
  Weig…                                                                         
  aver…                                                                         
  comm…             193,5…          192,032            193,171          191,6…  
  shar…                                                                         
  outs…                                                                         
  basic                                                                         
  Weig…                                                                         
  aver…                                                                         
  comm…             193,5…          192,032            195,214          196,8…  
  shar…                                                                         
  outs…                                                                         
  dilu…                                                                         
                                                                                
                                       7                                        
                                                                                
                          BIOMARIN PHARMACEUTICAL INC.                          
                                                                                
                                                                                
                     CONDENSED CONSOLIDATED BALANCE SHEETS                      
                                                                                
                                                                                
                    September 30, 2026 and December 31, 2025                    
                                                                                
            (In thousands of U.S. dollars, except per share amounts)            
                                                                                
                    September 30,                  December 31,                 
                    2026                           2025                         
 ────────────────────────────────────────────────────────────────────────────── 
                    -Unaudited                                                  
  ASSETS                                                                        
  Current                                                                       
  assets:                                                                       
  Cash and cash     $                   736,007    $                 1,311,679  
  equivalents                                                                   
  Short-term                                  —                        248,930  
  investments                                                                   
  Accounts                                                                      
  receivable,                         1,076,355                        908,214  
  net                                                                           
  Inventory                           1,796,069                      1,298,883  
  Other current                         312,205                        185,784  
  assets                                                                        
  Total current                       3,920,636                      3,953,490  
  assets                                                                        
  Noncurrent                                                                    
  assets:                                                                       
  Long-term                                   —                        492,242  
  investments                                                                   
  Property,                                                                     
  plant and                             980,081                        952,508  
  equipment, net                                                                
  Intangible                          4,777,247                        213,837  
  assets, net                                                                   
  Goodwill                              666,367                        196,199  
  Deferred tax                          897,787                      1,508,697  
  assets                                                                        
  Other assets                          327,113                        277,049  
  Total assets      $                11,569,231    $                 7,594,022  
  LIABILITIES                                                                   
  AND                                                                           
  STOCKHOLDERS’                                                                 
  EQUITY                                                                        
  Current                                                                       
  liabilities:                                                                  
  Accounts                                                                      
  payable and       $                   946,107    $                   759,031  
  accrued                                                                       
  liabilities                                                                   
  Current                                                                       
  portion of                            658,717                              —  
  long-term                                                                     
  debt, net                                                                     
  Total current                       1,604,824                        759,031  
  liabilities                                                                   
  Noncurrent                                                                    
  liabilities:                                                                  
  Long-term                           3,514,974                        597,176  
  debt, net                                                                     
  Other                                                                         
  long-term                             193,401                        150,816  
  liabilities                                                                   
  Total                               5,313,199                      1,507,023  
  liabilities                                                                   
  Stockholders’                                                                 
  equity:                                                                       
  Common stock,                                                                 
  $0.001 par                                                                    
  value:                                                                        
  500,000,000                                                                   
  shares                                                                        
  authorized;                                                                   
  193,676,831                               194                            192  
  and                                                                           
  192,300,101                                                                   
  shares                                                                        
  issued and                                                                    
  outstanding,                                                                  
  respectively                                                                  
  Additional                                                                    
  paid-in                             6,089,036                      5,956,582  
  capital                                                                       
  Company common                                                                
  stock held by                                                                 
  the                                                                           
  Nonqualified                          -10,851                        -10,508  
  Deferred                                                                      
  Compensation                                                                  
  Plan                                                                          
  Accumulated                                                                   
  other                                  -4,011                        -13,473  
  comprehensive                                                                 
  loss                                                                          
  Retained                              181,664                        154,206  
  earnings                                                                      
  Total                                                                         
  stockholders’                       6,256,032                      6,086,999  
  equity                                                                        
  Total                                                                         
  liabilities                                                                   
  and               $                11,569,231    $                 7,594,022  
  stockholders’                                                                 
  equity                                                                        
                                                                                
                                       8                                        
                                                                                
                          BIOMARIN PHARMACEUTICAL INC.                          
                                                                                
                                                                                
                CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS                 
                                                                                
                                                                                
                 Nine Months Ended September 30, 2026 and 2025                  
                                                                                
                         (In thousands of U.S. dollars)                         
                                                                                
                                  (Unaudited)                                   
                                                                                
  CASH FLOWS FROM         Nine Months Ended                                     
  OPERATING               September 30,                                         
  ACTIVITIES:             2026                                 2025             
 ────────────────────────────────────────────────────────────────────────────── 
  Net income              $                          27,458    $       395,474  
  Adjustments to                                                                
  reconcile net income                                                          
  to                                                                            
  net cash provided by                                                          
  operating                                                                     
  activities:                                                                   
  Depreciation and                                  244,514             59,119  
  amortization                                                                  
  Non-cash interest                                  30,548              1,969  
  expense                                                                       
  Stock-based                                       172,684            134,496  
  compensation                                                                  
  Impairment of assets                               15,203              2,967  
  Acquired IPR&D                                    282,258            220,963  
  expense                                                                       
  Deferred income                                   -27,490             48,125  
  taxes                                                                         
  Unrealized foreign                                                            
  exchange losses                                    -8,380                244  
  (gains)                                                                       
  Other                                              -7,091             -5,399  
  Changes in operating                                                          
  assets and                                                                    
  liabilities, net of                                                           
  effects of business                                                           
  acquired:                                                                     
                                                                                
  Accounts receivable,                              -60,435           -107,378  
  net                                                                           
  Inventory                                          -1,621            -98,796  
  Other current assets                              -54,369            -32,125  
  Other assets                                       12,859            -32,679  
  Accounts payable and                              -52,675            119,478  
  accrued liabilities                                                           
  Other long-term                                     3,511             21,892  
  liabilities                                                                   
  Net cash provided by                                                          
  operating                                         576,974            728,350  
  activities                                                                    
  CASH FLOWS FROM                                                               
  INVESTING                                                                     
  ACTIVITIES:                                                                   
  Purchases of                                                                  
  property, plant and                               -78,032            -62,316  
  equipment                                                                     
  Maturities and sales                              767,277            294,547  
  of investments                                                                
  Purchases of                                      -25,792           -313,262  
  investments                                                                   
  Business                                                                      
  combination, net of                            -5,067,630                  —  
  cash                                                                          
  acquired                                                                      
  Purchases of IPR&D,                              -277,881           -285,193  
  net of cash acquired                                                          
  Other investing                                    -1,191             -5,569  
  activities, net                                                               
  Net cash used in                               -4,683,249           -371,793  
  investing activities                                                          
  CASH FLOWS FROM                                                               
  FINANCING                                                                     
  ACTIVITIES:                                                                   
  Proceeds from                                                                 
  exercises of awards                                                           
  under                                               6,655              7,714  
  equity incentive                                                              
  plans                                                                         
  Taxes paid related                                                            
  to net share                                      -43,330            -53,265  
  settlement of equity                                                          
  awards                                                                        
  Proceeds from                                   3,650,000                  —  
  borrowings                                                                    
  Payments of debt                                  -65,605                  —  
  issuance costs                                                                
  Repayments of                                     -15,000                  —  
  borrowings                                                                    
  Net cash provided by                                                          
  (used in) financing                             3,532,720            -45,551  
  activities                                                                    
  Effect of exchange                                 -2,117             -3,740  
  rate changes on cash                                                          
  NET INCREASE                                                                  
  (DECREASE) IN CASH                               -575,672            307,266  
  AND CASH                                                                      
  EQUIVALENTS                                                                   
  Cash and cash                                                                 
  equivalents:                                                                  
  Beginning of period     $                       1,311,679    $       942,842  
  End of period           $                         736,007    $     1,250,108  
                                                                                
                                       9                                        
                                                                                
  Non-GAAP Information                                                          
                                                                                
The results presented in this press release include both GAAP information and
Non-GAAP information. Non-GAAP Income is defined by the company as GAAP Net
Income (Loss) excluding amortization, stock-based compensation expense and, in
certain periods, certain other specified items, as detailed below when
applicable. The company also includes a Non-GAAP adjustment for the estimated
tax impact of the reconciling items. Non-GAAP Cost of Sales (COS), Non-GAAP R&D
expenses and Non-GAAP Selling, General and Administrative (SG&A) expenses are
defined by the company as GAAP COS, GAAP R&D expenses and GAAP SG&A expenses,
respectively, excluding stock-based compensation expense and, in certain
periods, certain other specified items, as detailed below when applicable. Non-
GAAP Operating Margin percentage is defined by the company as GAAP Income (Loss)
from Operations, excluding amortization of intangible assets, stock-based
compensation expense and, in certain periods, certain other specified items,
divided by GAAP Total Revenues. Non-GAAP Diluted EPS is defined by the company
as Non-GAAP Income divided by Non-GAAP Weighted-Average Diluted Shares
Outstanding. Non-GAAP Weighted-Average Diluted Shares Outstanding is defined by
the company as GAAP Weighted-Average Diluted Shares Outstanding, adjusted to
include any common shares issuable under the company’s equity plans or
convertible debt in periods when they are dilutive under Non-GAAP. Non-GAAP
synergies is defined by the company as Amicus’ legacy labor and external spend
cost reductions, excluding the impact of stock-based compensation.

BioMarin regularly uses both GAAP and Non-GAAP results and expectations
internally to assess its financial operating performance and evaluate key
business decisions related to its principal business activities: the discovery,
development, manufacture, marketing and sale of innovative biologic therapies.
BioMarin also uses Non-GAAP Income internally to understand, manage and evaluate
its business and to make operating decisions, and compensation of executives is
based in part on this measure. Because these Non-GAAP metrics are important
internal measurements for BioMarin, the company believes that providing this
information in conjunction with BioMarin’s GAAP information enhances investors’
and analysts’ ability to meaningfully compare the company’s results from period
to period and to its forward-looking guidance, and to identify operating trends
in the company’s principal business.

Non-GAAP financial measures are not meant to be considered in isolation or as a
substitute for, or superior to comparable GAAP measures and should be read in
conjunction with the consolidated financial information prepared in accordance
with GAAP. Investors should note that the Non-GAAP information is not prepared
under any comprehensive set of accounting rules or principles and does not
reflect all of the amounts associated with the company’s results of operations
as determined in accordance with GAAP. Investors should also note that these
Non-GAAP financial measures have no standardized meaning prescribed by GAAP and,
therefore, have limits in their usefulness to investors. In addition, from time
to time in the future there may be other items that the company may exclude for
purposes of its Non-GAAP financial measures; likewise, the company may in the
future cease to exclude items that it has historically excluded for purposes of
its Non-GAAP financial measures. Because of the non-standardized definitions,
the Non-GAAP financial measure as used by BioMarin in this press release and the
accompanying tables may be calculated differently from, and therefore may not be
directly comparable to, similarly titled measures used by other companies.

The following tables present the reconciliation of GAAP reported to Non-GAAP
adjusted financial information:
                                       10                                       
                                                                                
    Reconciliation of GAAP Reported Information to Non-GAAP Information (1)     
                                                                                
              (In millions, except percentages and per share data)              
                                                                                
                                  (unaudited)                                   
                                                                                
                           Three                             Nine               
                          Months                           Months               
                           Ended                            Ended               
                       September                        September               
               2026          30,    2025         2026         30,    2025       
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  Reported                                                                      
  Net          $            -123    $     -31    $             27    $     395  
  Income                                                                        
  (Loss)                                                                        
  Adjustme…                                                                     
  Stock-ba…                                                                     
  compensa…                    4            4                  13           11  
  expense -                                                                     
  COS                                                                           
  Stock-ba…                                                                     
  compensa…                   14           15                  41           41  
  expense -                                                                     
  R&D                                                                           
  Stock-ba…                                                                     
  compensa…                   36           30                 119           83  
  expense -                                                                     
  SG&A(2)                                                                       
  Amortiza…                                                                     
  of                          99            5                 177           15  
  intangib…                                                                     
  assets                                                                        
  Amortiza…                                                                     
  of                                                                            
  acquired                    18            —                  29            —  
  inventory                                                                     
  step-up -                                                                     
  COS(3)                                                                        
  Acquisit…                                                                     
  and                                                                           
  restruct…                   47           15                 143           15  
  costs -                                                                       
  SG&A(4)                                                                       
  Loss on                      —            —                   —            3  
  investme…                                                                     
  Income                                                                        
  tax                        -50          -16                -120          -38  
  effect of                                                                     
  adjustme…                                                                     
  Non-GAAP     $              45    $      22    $            430    $     525  
  Income                                                                        
                                                                                
                                                                                
        Thr…                                                                    
        Mon…                                                                    
        End…                                                                    
        Sep…                                                                    
        30,                                                                     
        2026                                 2025                               
        COS          R&D         SG…         COS          R&D         SG…       
 ────────────────────────────────────────────────────────────────────────────── 
  G…    $     205    $    181    $    334    $     140    $    189    $    268  
  e…                                                                            
  A…                                                                            
  S…                                                                            
  c…           -4         -14         -36           -4         -15         -30  
  e…                                                                            
  A…                                                                            
  of                                                                            
  a…          -18           —           —            —           —           —  
  i…                                                                            
  s…                                                                            
  A…                                                                            
  a…            —           —         -47            —           —         -15  
  r…                                                                            
  c…                                                                            
  N…    $     184    $    167    $    249    $     136    $    174    $    223  
  e…                                                                            
                                                                                
                                                                                
        Ni…                                                                     
        Mo…                                                                     
        En…                                                                     
        Se…                                                                     
        30,                                                                     
        20…                                  2025                               
        COS         R&D         SG&A         COS          R&D         SG…       
 ────────────────────────────────────────────────────────────────────────────── 
  G…    $    603    $    566    $     987    $     442    $    509    $    707  
  e…                                                                            
  A…                                                                            
  S…                                                                            
  c…         -13         -41          -1…          -11         -41         -83  
  e…                                                                            
  A…                                                                            
  of                                                                            
  a…         -29           —            —            —           —           —  
  i…                                                                            
  s…                                                                            
  A…                                                                            
  a…           —           —          -1…            —           —         -15  
  r…                                                                            
  c…                                                                            
  N…    $    561    $    525    $     724    $     431    $    468    $    609  
  e…                                                                            
                                                                                
                                       11                                       
                                                                                
         …    …                  …             …    …                  …        
         …    …                  …             …    …                  …        
         …    …                  …             …    …                  …        
         …    …                  …             …    …                  …        
      …  …    …          …       …          …  …    …          …       …        
 ────────────────────────────────────────────────────────────────────────────── 
      $  …       …  %    $  …       …  %    $  …       …  %    $  …       …  %  
                                                                                
         …       …          …       …          …       …          …       …     
         …       …          5       …          …       …          …       …     
         …       …          —       —          …       …          —       —     
         …       …          …       …          …       …          …       …     
      $  …       …  %    $  …       …  %    $  …       …  %    $  …       …  %  
                                                                                
                                                                                
                        Three                              Nine                 
                       Months                            Months                 
                        Ended                             Ended                 
                    September                         September                 
              2026        30,    2025           2026        30,    2025         
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  Diluted     $         -0.63    $     -0.16    $          0.14    $      2.04  
  EPS                                                                           
  Adjustm…                                                                      
  Stock-b…                                                                      
  compens…    $          0.28    $      0.25               0.87           0.69  
  expense…                                                                      
  Amortiz…                                                                      
  of          $          0.51    $      0.03               0.89           0.08  
  intangi…                                                                      
  assets                                                                        
  Amortiz…                                                                      
  of                                                                            
  acquired    $          0.09    $         —               0.15              —  
  invento…                                                                      
  step-up…                                                                      
  Acquisi…                                                                      
  and         $          0.24    $      0.08               0.72           0.08  
  restruc…                                                                      
  costs(4)                                                                      
  Loss on     $             —    $         —                  —           0.02  
  investm…                                                                      
  Income                                                                        
  tax                                                                           
  effect      $         -0.26    $     -0.08              -0.60          -0.19  
  of                                                                            
  adjustm…                                                                      
  Non-GAAP                                                                      
  Diluted     $          0.23    $      0.12    $          2.18    $      2.69  
  EPS                                                                           
                                                                                
                                                                                
           Three                          Nine                                  
           Mont…                          Months                                
           Ended                          Ended                                 
           Sept…                          Septe…                                
             30,                          30,                                   
            2026           2025                     2026           2025         
  GAAP                                                                          
  Weig…                                                                         
  Dilu…           193.6          192.0                    195.2          196.9  
  Shar…                                                                         
  Outs…                                                                         
  Adju…                                                                         
  Comm…                                                                         
  stock                                                                         
  issu…                                                                         
  under             2.5            0.8                        —              —  
  the                                                                           
  comp…                                                                         
  equi…                                                                         
  plans                                                                         
  Comm…                                                                         
  stock                                                                         
  issu…                                                                         
  under               —              —                      4.4              —  
  the                                                                           
  comp…                                                                         
  conv…                                                                         
  debt                                                                          
  Non-…                                                                         
  Weig…                                                                         
  Dilu…           196.0          192.8                    199.6          196.9  
  Shar…                                                                         
  Outs…                                                                         
                                                                                
(1) Certain amounts may not sum or recalculate due to rounding.

(2) Stock-based compensation expense recorded in SG&A for the nine months ended
September 30, 2026, includes approximately $13 million related to the post-
combination service period for unvested Amicus stock options.

(3) Represents amortization of the inventory step-up for the inventory acquired
in the Amicus transaction.

(4) The 2026 amounts represent severance, transaction and integration costs
resulting from the Amicus acquisition, as well as restructuring costs incurred
in connection with corporate initiatives. The 2025 amounts represent severance
costs incurred in connection with the acquisition of Inozyme Pharma, Inc.

(5) Represents impairment loss on non-marketable equity securities recorded in
Other income, net, in the first quarter of 2025.

(6) Common stock issuable under the company’s equity plans and convertible debt
were excluded from the computation of GAAP and Non-GAAP Weighted-Average Diluted
Shares Outstanding in the periods they were anti-dilutive.
                                       12                                       

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BMRN/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.